Waters Corporation

Waters Corporation delivers double-digit organic growth in Q3 2026, raises full-year revenue guidance by $43 million, and announces MOBILion acquisition to lead Discovery Proteomics.

Waters Corporation reported Q3 2026 total as-reported revenue of $1.767 billion, with organic revenue of $871 million growing 10% in constant currency — at the high end of guidance — while acquired Biosciences and Diagnostic Solutions delivered $896 million, 1% reported growth, slightly ahead of plan. Adjusted EPS grew 21% to $4.10, driven by top-line momentum, cost synergies flowing through the P&L ahead of schedule, and operational leverage. Management raised full-year 2026 total revenue guidance by $43 million at the midpoint to approximately $6.479–$6.497 billion and provided a 2027 starting framework of mid-single-digit-plus combined organic growth with 100 basis points of adjusted operating margin expansion to 29.2%.

Waters Corporation is a Delaware-incorporated analytical instruments company headquartered in Milford, Massachusetts. Following its 2025 acquisition of the BD Biosciences and Diagnostic Solutions business (BDS Business), Waters operates as a significantly larger combined life science tools and diagnostics platform. The company sells instruments, software, and consumables to pharmaceutical, industrial, and clinical customers globally.

Primary products

• LC-MS instruments (Xevo MRT, Xevo TQ Absolute XR IVD)
• HPLC systems (Alliance iS)
• Chemistry consumables (MaxPeak Premier Columns)
• Empower chromatography data software
• Flow cytometry instruments and reagents (FACSDiscover A7, A8, S8)
• Microbiology systems (BACTEC FXI culture system)